Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

NCT00405392 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

365

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG: Ibandronate (SB743830HD)

Sponsor

GlaxoSmithKline